• Enhancing Immunity

    Veterinary Medicine: Helping Animals Fight Infections by Enhancing Their Immune Response

Complex infectious diseases remain a key challenge in animal husbandry despite the availability of effective veterinary medicines. Vaccines and antibiotics are commonly used, but they are only effective against specific pathogens. Stimulation of the innate immune system has been shown to provide a rapid, potent and broad protective response to infectious agents. Scientists at Bayer are exploring the potential of immunostimulants to help veterinarians and producers around the world better mitigate infectious diseases in livestock. Daniel Keil, Director of Clinical Development at Bayer HealthCare Animal Health North America, has worked together with a multi-disciplinary team of Bayer scientists to develop Immunostimulatory DNA for veterinary use. This product is based on technology developed by Juvaris BioTherapeutics and is patent protected. The Animal Health applications are being exclusively developed by Bayer Animal Health and are the subject of Bayer patent applications.

Story check

  • Challenge
    Complex infectious diseases in livestock remain a key challenge despite the availability of effective veterinary healthcare products. Vaccines are useful in protecting livestock against specific pathogens while antibiotics act only on those organisms that are susceptible.
  • Solution
    Bayer scientists are exploring the use of Immunostimulatory DNA to stimulate the animals' innate immune system.
  • Benefits
    The stimulation of the innate immune system has been shown to provide a rapid, potent and broad protective response against disease causing pathogens.

Interview: Dr. Artur Summerfield

Dr. Artur Summerfield

„Reduce the Infection Pressure“

research spoke with Dr. Artur Summerfield, professor of Veterinary Immunology at the University of Bern, about opportunities for immunostimulation in veterinary medicine.

What’s the significance of this advancement in ­Immunostimulatory DNA?

Immunostimulatory DNA enhances the immune system’s ability to react to microbial infection by putting the immune system into an alarm status. This can be beneficial for animals as it can potentially protect them at times when they are exposed to multiple pathogens or other stressors. Animals with stronger immune defenses are likely to withstand infections better, which could reduce antimicrobial use, lessen animal suffering and minimize economic impact.

How can immunostimulants benefit animal husbandry?

Vaccines, antimicrobial therapies and good animal husbandry practices will always be important. Immunostimulants will complement these approaches, offering veterinarians and producers an innovative non-antibiotic option that can help enhance animals’ natural defenses and reduce the infection pressure. This would benefit animals as well as consumers.

Molecular Disease Pattern

The development of immunity in response to an infection consists of two components: Acquired immunity, which protects the animals against pathogens very specifically. However, it takes 2-4 weeks for the adaptive immunity to become effective. Innate immunity is the first to recognize the presence of a pathogen and endeavors to keep it in check during the time it takes the adaptive immune system to respond to the pathogen. Therefore, the key is the timely trigger of innate immunity. "The innate immune system recognizes the typical molecular patterns of disease pathogens and tackles them immediately," explains Dr. Daniel Keil, Director of Clinical Development at Bayer HealthCare Animal Health North America. "Immunostimulatory DNA contains the same pattern as the pathogens." Keil, together with a multi-disciplinary team of Bayer scientists, successfully developed a stable and effective Immunostimulatory DNA for veterinary use. This product is based on technology developed by Juvaris BioTherapeutics and is patent protected. Animal Health applications are being exclusively developed by Bayer Animal Health and are the subject of Bayer patent applications. This innovative immunostimulant will be available in the US for use in cattle and poultry in the fall of 2015, and has the potential to change the way we approach infectious diseases in animals.

Enhancing immunity
International Users
This website is checked, operated and updated by BAYER at Leverkusen, Germany. It is intended for international use. However BAYER gives no guarantee that the details presented on this website are correct worldwide, and, in particular, that products and services will be available with the same appearance, in the same sizes or on the same conditions throughout the world. Should you call up this website or download contents, please note that it is your own responsibility to ensure that you act in compliance with local legislation applicable in that place.Products mentioned on this website may come in different packaging, in different package sizes, or with different lettering or markings, depending on the country.
In the USA the business of the Bayer Group is conducted by Bayer Corporation. Customers in the USA are requested to address to this entity.